Peptide Skeleton Protection for RA Bone Erosion Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for rheumatoid arthritis, such as Humira and Xeljanz, fail to provide sustained remission and are associated with safety concerns, and there is a need for a method to protect the skeleton from erosion and maintain bone integrity in patients with rheumatoid arthritis.
Innovation Solution
Administering a peptide with the amino acid sequence of SEQ ID NO: 1 to inhibit the proliferation and migration of synoviocytes, thereby protecting the skeleton by ameliorating bone erosion, maintaining bone mineral density, and preventing cartilage and joint damage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional drugs like tofacitinib are used to treat rheumatoid arthritis, then immune system suppression and inflammation reduction are achieved, but safety concerns arise including blood clot formation, liver enzyme abnormalities, elevated cholesterol, severe infections, and cancers
Solution Approach 1:
The patent extracts and targets the specific pathological mechanism of FLS-mediated bone erosion, rather than using broad immunosuppression. The peptide specifically inhibits FLS proliferation and osteoclast differentiation, removing the harmful side effects of systemic immunosuppression while maintaining targeted therapeutic effectiveness against bone erosion in rheumatoid arthritis
Solution Approach 2:
The peptide acts as a specific intermediary molecule that blocks the interaction between FLS and osteoclasts by inhibiting FLS proliferation and RANKL expression. This intermediary action specifically addresses bone erosion without the need for broad immunosuppression, thereby achieving treatment effectiveness while avoiding the safety concerns associated with conventional drugs
2Reliability
If FLS proliferation and migration are not inhibited, then synovial hyperplasia and cartilage invasion progress, but conventional therapies fail to provide sustained remission
Solution Approach 1:
The peptide is administered to prevent FLS proliferation and migration before they can cause extensive synovial hyperplasia and cartilage invasion. By acting preliminarily on FLS, the peptide prevents the progression to advanced disease stages, achieving sustained remission while preserving synovial tissue integrity
Solution Approach 2:
The patent converts the aggressive behavior of FLS from a harmful force into a therapeutic target. By specifically inhibiting FLS proliferation and migration, the peptide transforms the pathological process into a controlled therapeutic mechanism, achieving sustained remission while protecting synovial tissue from destruction
3Strength
If bone resorption is not inhibited, then bone erosion progresses and skeleton integrity deteriorates, but existing treatments do not adequately protect the skeleton
Solution Approach 1:
The peptide serves as a specific intermediary that blocks the FLS-osteoclast interaction pathway by inhibiting FLS proliferation and RANKL expression. This intermediary action specifically prevents bone resorption and erosion while preserving bone mass and maintaining skeleton integrity, addressing the unmet need for skeleton protection in rheumatoid arthritis
Solution Approach 2:
The patent extracts and specifically targets the bone erosion pathway mediated by FLS and osteoclasts, separating it from general inflammation. By specifically inhibiting this pathway through FLS proliferation and migration inhibition, the peptide protects bone mass and skeleton integrity without requiring broad immunosuppression that fails to provide adequate skeleton protection
Data Source
AI summary
Provided is a skeleton protection method, which comprises administering to a subject in need thereof an effective amount of a peptide comprising the amino acid sequence of SEQ ID NO: 1. The present invention proves that administering the peptide of SEQ ID NO: 1 can ameliorate cortical bone erosion of calcaneus bone resulting from rheumatoid arthritis (RA) and restore the decline of RA-induced bone mineral density. Therefore, the peptide of SEQ ID NO: 1 possesses a therapeutic effect for skeleton protection.